QSAR in Development of Antidepressants
QSAR in Development of Antidepressants QSAR in Development of Antidepressants
Outline • Depression as a disease • Treatment Past, Present, and Future • Determining the target • QSAR model • Proposed lead • Synthetic method • Conclusions & Questions
Depression as a Disease • 1 out 5 adults affected by depression • 11 th most common reason for visiting doctor • By 2020 2 nd largest cause for illness induced disability • 3 rd most commonly sold drug • lifetime risk – 12.7% male – 21.3% female
- Page 1: The Next Generation of Antidepressa
- Page 5 and 6: Serotonin Hypothesis • serotonerg
- Page 7 and 8: Serotonin effect Phil Skolnick, P.
- Page 9 and 10: Project Aim • explore a faster ac
- Page 11 and 12: QSAR Design • Create training set
- Page 13 and 14: Why use GFA • builds multiple mod
- Page 15 and 16: • r 2 =.87 QSAR results • valid
- Page 17 and 18: Strategy Nh 2 fluoxetine F Cl O H N
- Page 19 and 20: Synthetic scheme S antidepressants
- Page 21 and 22: Synthetic scheme
- Page 23: References • Phil Skolnick, P. P.
Depression as a Disease<br />
• 1 out 5 adults affected by depression<br />
• 11 th most common reason for visit<strong>in</strong>g<br />
doctor<br />
• By 2020 2 nd largest cause for illness<br />
<strong>in</strong>duced disability<br />
• 3 rd most commonly sold drug<br />
• lifetime risk<br />
– 12.7% male<br />
– 21.3% female
Change language